Antibacterial Agents TRIZ Cases

Phage display identifies peptides binding PNAG to reduce bacterial loads by 50%, avoiding live vaccine risks and high antibiotic costs.

High penetration prodrugs covalently link functional units to transportational units via linkers to enhance antimicrobial bioavailability.

Arylphenoxypropionate derivatives inhibit the AccD6 enzyme to disrupt fatty acid biosynthesis, addressing drug resistance and shortening treatment duration.

Deuterium substitution at specific molecular positions extends half-life and reduces adverse events via the kinetic isotope effect.

Isoprenoidal essential oil combined with microdermabrasive particles cleans eye area tissue.

Modifying DLP4-derived peptide ID13 reduces cytotoxicity while maintaining potent activity against Staphylococcus aureus.

Novel cyclic peptide compounds reduce nephrotoxicity while maintaining antibacterial activity against polymyxin-resistant bacteria.

Indoline sulfonyl compounds bridge zinc atoms in dimetalloenzymes, resolving stability issues of traditional thiol inhibitors.

Novel culture medium formulation accelerates mycobacterial growth using fatty acid-free bovine serum albumin and long chain fatty acids.

Hydrolyzed tetravalent metal salts inhibit biofilm formation without triggering antimicrobial resistance or toxicity.

Anthranilyl-adenosinemonosulfamate analogs inhibit the PqsA enzyme to block PQS and HHQ biosynthesis.

Peptide inhibitors block the STAT3-IL10 pathway to stimulate host immunity, reducing bacterial load while avoiding prolonged antibiotic exposure.

Intraperitoneal administration of granulocyte-macrophage colony-stimulating factor combined with antimicrobial agents targets the peritoneal cavity directly.

Antibodies targeting the ClfA N3 site neutralize bacterial virulence by blocking fibrinogen binding, bypassing pathogen immune evasion mechanisms.

An activated-quenched polysaccharide reference standard enables accurate nephelometric quantification of vaccine components.

NP16 compounds inhibit CrtN enzymes to block staphyloxanthin biosynthesis, reducing S. aureus virulence without inducing antibiotic resistance.

PARP7 inhibitors transform cold tumors into hot microenvironments by activating STING pathways, overcoming checkpoint inhibitor limitations.

Engineered fibroblastic reticular cell-derived vesicles target kidneys via anchor peptides, addressing sepsis-associated acute kidney injury.

Segmented amphiphilic carriers accumulate drugs via interactive domains, resolving low loading capacity and instability in moderate hydrophobicity formulations.

An oral pharmaceutical composition combines a monoclonal anti-TNFα antibody with caprylic acid for targeted intestinal delivery.

A biodegradable antimicrobial accessory uses an antioxidant topcoat to protect polymer components from oxidation.

Reactive oxychlorine species and magnesium chloride formulation for mucosal decolonization.

Liquid pattern sequences compensate for surfactant depletion to prevent pitting in solidified layers during nano-imprint lithography.

Composite herbal extracts simultaneously inhibit TGF-β, TNF-α, and IL-1β pathways to treat lung fibrosis without complex multi-drug regimens.

Hydrocarbon staples stabilize Esculentin-1A derived peptides, resolving structural instability and proteolytic lability while minimizing host membrane toxicity.

Steglich esterification merges Thymol and Carvacrol into a single compound that overcomes antibiotic resistance in acute gastroenteritis treatment.

A CAR cell library integrates genetic circuits and inducible proteins to enable programmable expression regulation.

Lactobacillus fermentum PL9 overcomes weak tight junction stimulation by adhering strongly to the intestinal mucosa and stimulating occludin production.

Humanized anti-CCL20 antibodies neutralize CCL20 to overcome primary non-responsiveness in current biologic therapies.

LSP1 bacteriophage selectively eradicates Fusimonas intestini without disrupting intestinal flora, avoiding antibiotic resistance.

Self-assembling lipopeptide bundles form synthetic virus-like particles to enhance vaccine immunogenicity without toxic adjuvants.

A roller adhesive removes surface debris to expose bacteria in skin pores before applying an antibacterial agent.

Specific yeast strains like Sporidiobolus pararoseus generate high-value lipids, reducing production costs while maintaining precise fatty acid compositions.

Hydrazide-carbonyl linkages prevent oxidative cleavage of saccharide rings during synthesis, preserving glycan integrity and binding affinity.

A polymeric film-forming sealant applied to tonsil tissue inhibits bacterial colonization and promotes hemostasis.

Metal organic frameworks encapsulate NONOates to enable controlled nitric oxide release.

Zinc ions and borate complexes deliver preservative efficacy without conventional agents, preventing corneal toxicity.

Humanizing mouse antibody sequences reduces immunogenicity while maintaining therapeutic efficacy against MAdCAM.

Enzymes degrade the extracellular polymeric substance matrix, resolving antibiotic resistance in respiratory biofilm infections.

Controlled crystallization yields a thermodynamically stable type I crystal, preventing polymorphic transitions and ensuring photostability.

Combining zidovudine with carbapenems generates synergistic antimicrobial activity against log phase and clinically latent microorganisms.

Expand adult stem cells from peripheral blood using Macrophage Colony Stimulating Factor treatment and Ficoll gradient purification.

A bacteriophage composition targets and lyses Pseudomonas aeruginosa strains through specific viral infection mechanisms.

Neutralizing anti-TLR4 antibodies block pro-inflammatory signaling in patients with elevated ligand levels.

Reverse microemulsions solubilize hydrophilic agents in volatile solvents, resolving skin delivery inefficiencies and enabling painless penetration.

Non-lipidated ORF2086 variants overcome pyruvylation issues and expression instability while maintaining immunogenicity via adjuvant mediation.